Lopez LR, Miller CM, Jeyachandran JN, Li C, Simpson KW, Arthur JC. Heterogeneity among clinical intestinal escherichia coli isolates upon acquired streptomycin resistance. Microbiol Spectr. 2023 Jun 15;11(3):e035022. doi: 10.1128/spectrum.03500-22
Earnshaw S, McDade C, Bryan A, Ines M, Micallef C, Sung A, Enoch DA. Erratum for Earnshaw et al., Real-world financial and clinical impact of diagnostic-driven and empirical-treatment strategies in high-risk immunocompromised patients with suspected aspergillus infection in the United Kingdom. Microbiol Spectr. 2022 Oct 26;10(5):e0303122. doi: 10.1128/spectrum.03031-22
Earnshaw S, McDade C, Bryan A, Ines M, Micallef C, Sung A, Enoch D. Real-world financial and clinical impact of diagnostic-driven and empirical-treatment strategies in high-risk immunocompromised patients with suspected aspergillus infection in the United Kingdom. Microbiol Spectr. 2022 Jun 29;10(3):e0042522. doi: 10.1128/spectrum.00425-22
Porter W, Mahajan P, Danysh HE, Chelius DC. Socioeconomic determinants of pediatric papillary thyroid cancer: a SEER database review. Poster presented at the 87th Annual Meeting of the American Thyroid Association; October 21, 2017. Victoria, Canada. [abstract] Thyroid. 2017 Oct; 27(S1):A135-6.
Mahajan P, Danysh HE, Chelius DC, Venkatramani R. Characteristics and outcomes of children and adolescents with low-risk papillary thyroid carcinoma in the SEER database. Poster presented at the 87th Annual Meeting of the American Thyroid Association; October 20, 2017. Victoria, Canada. [abstract] Thyroid. 2017 Oct; 27(S1):A92.
Mahajan P, Danysh HE, Chelius DC, Venkatramani R. Characteristics and outcomes of children and adolescents with high-risk papillary thyroid carcinoma in the SEER database. Poster presented at the 87th Annual Meeting of the American Thyroid Association; October 20, 2017. Victoria, Canada. [abstract] Thyroid. 2017 Oct; 27(S1):A92-3.
Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.